BioCentury | Feb 21, 2020
Emerging Company Profile

Montis: Exploring an untouched macrophage subset in immuno-oncology

...as many weeks. Droia, which teamed up with the Flanders Institute for Biotechnology (VIB) and Catholic University Leuven...
BioCentury | Jul 19, 2019
Regulation

A half step forward for heart failure as FDA guidance leaves key question unanswered

...be better correlated with mortality and morbidity. HOMAGE is an academic collaboration coordinated by the University of Leuven...
BioCentury | Jul 3, 2019
Clinical News

July 3 Clinical Quick Takes: GSK starts Phase III otilimab RA program; plus Unum, Xofluza and more

...identified. Akkermansia improves metabolic parameters in overweight, obese volunteers A team including researchers from Catholic University of Leuven...
BioCentury | Jun 18, 2019
Finance

Imcyse to test cell killing approach in autoimmune disease with €35M in new funding

...Federal Holding and Investment Company (SFPI), as well as prior investors Biogenosis, Noshaq and Catholic University of Leuven....
BioCentury | Nov 2, 2018
Targets & Mechanisms

Rethinking definitions of autoimmune disease

...different clinically often share the same immunology and genetics,” said Adrian Liston, group leader at Catholic University Leuven’s...
...to requests to comment. Companies and Institutions Mentioned Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Catholic University Leuven...
BioCentury | Sep 20, 2018
Distillery Therapeutics

Cancer

...et al. Cancer Res. ; published online Sept. 5, 2018 doi:10.1158/0008-5472.CAN-18-0250 CONTACT: Kim R. Kampen, Catholic University Leuven...
BioCentury | Sep 1, 2018
Politics, Policy & Law

Back to School 2018: A pathway to Biopharma 3.0

...either for first diagnosis or after relapse. UCB also started the SeizeIT consortium, together with Catholic University Leuven...
...South San Francisco, Calif. Blue Cross Blue Shield Association, Chicago, Ill. Brii Biosciences, Shanghai, China Catholic University Leuven...
BioCentury | Aug 31, 2018
Company News

AbbVie exercises option for argenx cancer candidate

...deal” ). ARGX-115 is an antibody targeting leucine-rich repeat containing 32 (LRRC32; GARP). Researchers at Catholic University Leuven...
...Medicine in 2015. argenx has worldwide rights to ARGX-115 from the de Duve Institute at Catholic University Leuven...
BioCentury | Aug 22, 2018
Company News

AbbVie exercises option for argenx cancer candidate

...mAb” ). ARGX-115 is an antibody targeting leucine-rich repeat containing 32 (LRRC32; GARP). Researchers at Catholic University Leuven...
...Medicine in 2015. argenx has worldwide rights to ARGX-115 from the de Duve Institute at Catholic University Leuven...
BioCentury | Jul 27, 2018
Emerging Company Profile

Wound-up bacteria

...Preclinical Founded: 2016 by Evelina Vågesjö, Stefan Roos and Mia Phillipson University collaborators: Uppsala University, Catholic University Leuven...
Items per page:
1 - 10 of 121
BioCentury | Feb 21, 2020
Emerging Company Profile

Montis: Exploring an untouched macrophage subset in immuno-oncology

...as many weeks. Droia, which teamed up with the Flanders Institute for Biotechnology (VIB) and Catholic University Leuven...
BioCentury | Jul 19, 2019
Regulation

A half step forward for heart failure as FDA guidance leaves key question unanswered

...be better correlated with mortality and morbidity. HOMAGE is an academic collaboration coordinated by the University of Leuven...
BioCentury | Jul 3, 2019
Clinical News

July 3 Clinical Quick Takes: GSK starts Phase III otilimab RA program; plus Unum, Xofluza and more

...identified. Akkermansia improves metabolic parameters in overweight, obese volunteers A team including researchers from Catholic University of Leuven...
BioCentury | Jun 18, 2019
Finance

Imcyse to test cell killing approach in autoimmune disease with €35M in new funding

...Federal Holding and Investment Company (SFPI), as well as prior investors Biogenosis, Noshaq and Catholic University of Leuven....
BioCentury | Nov 2, 2018
Targets & Mechanisms

Rethinking definitions of autoimmune disease

...different clinically often share the same immunology and genetics,” said Adrian Liston, group leader at Catholic University Leuven’s...
...to requests to comment. Companies and Institutions Mentioned Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Catholic University Leuven...
BioCentury | Sep 20, 2018
Distillery Therapeutics

Cancer

...et al. Cancer Res. ; published online Sept. 5, 2018 doi:10.1158/0008-5472.CAN-18-0250 CONTACT: Kim R. Kampen, Catholic University Leuven...
BioCentury | Sep 1, 2018
Politics, Policy & Law

Back to School 2018: A pathway to Biopharma 3.0

...either for first diagnosis or after relapse. UCB also started the SeizeIT consortium, together with Catholic University Leuven...
...South San Francisco, Calif. Blue Cross Blue Shield Association, Chicago, Ill. Brii Biosciences, Shanghai, China Catholic University Leuven...
BioCentury | Aug 31, 2018
Company News

AbbVie exercises option for argenx cancer candidate

...deal” ). ARGX-115 is an antibody targeting leucine-rich repeat containing 32 (LRRC32; GARP). Researchers at Catholic University Leuven...
...Medicine in 2015. argenx has worldwide rights to ARGX-115 from the de Duve Institute at Catholic University Leuven...
BioCentury | Aug 22, 2018
Company News

AbbVie exercises option for argenx cancer candidate

...mAb” ). ARGX-115 is an antibody targeting leucine-rich repeat containing 32 (LRRC32; GARP). Researchers at Catholic University Leuven...
...Medicine in 2015. argenx has worldwide rights to ARGX-115 from the de Duve Institute at Catholic University Leuven...
BioCentury | Jul 27, 2018
Emerging Company Profile

Wound-up bacteria

...Preclinical Founded: 2016 by Evelina Vågesjö, Stefan Roos and Mia Phillipson University collaborators: Uppsala University, Catholic University Leuven...
Items per page:
1 - 10 of 121